Trial
NCT04242173
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Regeneron Pharmaceuticals
Condition
Cutaneous Squamous Cell Carcinoma
Intervention
Cemiplimab-Rwlc
Why stopped
Lack of Interest
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-04